Navigation Links
Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
Date:5/10/2010

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

In patients with type 1 diabetes, T cells of the immune system attack and destroy beta cells that are located in the pancreas and make insulin. Teplizumab works by binding to CD3 receptors on the surface of the T cells and, by doing so, may modulate the autoimmune attack on pancreatic beta cells and preserve or protect these cells. If effective, patients may require less injected insulin and their blood glucose levels may be easier to control.

In an earlier trial of teplizumab, a small group of subjects with diabetes of recent onset were noted to have improved function of their beta cells, improved glucose control, and reduced insulin requirements for up to two years. These findings are being further studied in the Protege and Protege Encore clinical trials.

The Protege Encore trial is designed to determine if teplizumab can preserve pancreatic insulin production, which may make diabetes easier to manage. "We have a lot of enthusiasm about the teplizumab studies and their implications. It is hoped that one day we can offer a new treatment option to help patients better manage their disease," Dr. Hays commented.

Approximately 125 study sites across 16 countries will be enrolling 400
'/>"/>

SOURCE Richard M. Hays, M.D., P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
9. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
10. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of Vitae ... VTAE -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether Vitae Pharmaceuticals and certain of its officers ...
(Date:3/2/2015)... 2015  CANTEL MEDICAL CORP. (NYSE: CMN ... CEO, will be presenting at the Sidoti & Company ... presentation is scheduled for 2:00 PM ET on Monday, ... New York . In addition, Mr. Krakauer, ... be available for separate one-on-one meetings during the day. ...
(Date:3/2/2015)... 2, 2015  CytomX, a biotechnology company developing ... announced the creation of scientific and clinical advisory ... the fields of cancer immunotherapy and antibody drug ... will provide guidance to CytomX on the development ... and Probody drug conjugates. The company identified advisors ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
(Date:3/2/2015)... 02, 2015 The minimally invasive ... a CAGR of 6.1% to reach $14,133.0 million ... , Factors such as advantages of minimally invasive ... owing to minimally invasive surgeries and increasing number ... driving the global minimally invasive surgical instruments market. ...
(Date:3/2/2015)... Wailea, Maui Hawaii (PRWEB) March 02, 2015 ... Five-Star resort, is celebrating its 25th anniversary this year, having ... commemorate the milestone, the luxury resort is honoring over 70 ... at the resort -- from amongst the approximately 400 original ... dinner on the Resort’s Oceanfront Lawn. , This ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The Alliance ... fire safety expert Mark Chubb to serve as chief ... safety operations and training in Bangladesh and guide remediation ... , “Mark will ensure that the Alliance continues ... safety programs for Bangladesh garment workers,” said Alliance Independent ...
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Metamora, Michigan (PRWEB) March 01, 2015 ... approved to treat Overactive Bladder (OAB) symptoms, such as a ... adults when another type of medication (anticholinergic) does not work ... different treatment option that takes another approach to targeting the ... BOTOX® works on the nerves and bladder muscle, blocking the ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... BruxZir Solid Zirconia, ... bridge with no porcelain overlay. This new restoration proves strong, reliable and esthetic because of ... ... innovation from Glidewell Dental Lab , is a full-contour solid zirconia crown or bridge ...
... ... thought his story was worth telling. After being diagnosed with Parkinson,s disease ... a manuscript about the experience. Not only could he not find a ... even reading sample chapters. Believing the story needed to be told, Bill ...
... , ... an Atlanta based antivirus company specializing in threat prevention and cloud based antivirus solutions, ... powered mobile devices operate cross carrier and worldwide with Google reporting 60,000 Android handsets ... ...
... ... 32nd Annual National Martial Arts Festival at the Cherry Hill Crowne Plaza Hotel in Cherry Hill, ... (PRWEB) July 1, 2010 -- ... movies, head to Cherry Hill, N.J. The U.S. Soo Bahk Do Moo Duk Kwan Federation, ...
... is already one of medicine,s most successful transplant procedures, ... Now, for the first time, a team of German ... of transplanted corneas are more likely in patients whose ... to surgery. The meta-analysis report appears in July ...
... PA, July 1, 2010 About 1 in 200 women ... 75% of these low-risk, single-baby births planned in advance as ... American Journal of Obstetrics & Gynecology ( AJOG ... results of multiple studies from around the world. They report ...
Cached Medicine News:Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 2Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 3Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 4Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 2Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 3Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 4Health News:Bluepoint Security Launches World's First Cloud Antivirus For The Google Android Mobile Platform 2Health News:700 Karate Kids to Converge on Cherry Hill, NJ July 8-10, 2010 2Health News:Study finds new key to corneal transplant success 2Health News:Planned home births associated with tripling of neonatal mortality rate vs. planned hospital births 2
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: